Filter by: patients
Home > Community Treatment Reports and Side Effects > Levocarb Treatment Report
What is Levocarb?

Levocarb is a brand name for a combination of carbidopa and levodopa used for the treatment of Parkinson's disease. Levodopa is the metabolic precursor of dopamine whilst carbidopa decreases the metabolism of dopamine in the body thereby increasing its effectiveness.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Parkinsonism 2 0
Other 1 1 Efficacy_slight

See all 2 patients currently taking Levocarb

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 1
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with Levocarb

None 1

Reported Dosages

  5 mg daily 300 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Levocarb (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 100%
Doctor's advice 1   Doctor's advice: 100%
Other 1   Other: 100%

See all 1 patient who’ve stopped taking Levocarb

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Levocarb

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Levocarb

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Levocarb

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Levocarb

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of Levocarb

$200+
 1 100%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 0 0%

Report created on May 24, 2012.